Trials / Completed
CompletedNCT04883827
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
Detailed description
Primary Objective: \- Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy Exploratory Objective: \- Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood collection | 20-40 mL of blood to extract cell free DNA |
| OTHER | Urine collection | up to 15 mL of urine to extract cell free DNA |
Timeline
- Start date
- 2021-01-06
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2021-05-12
- Last updated
- 2024-10-22
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04883827. Inclusion in this directory is not an endorsement.